The NDA for 18F-DCFPyL-PET/CT being considered by the FDA also includes supportive data from the phase 2/3 OSPREY trial, in which 18F-DCFPyL-PET/CT was assessed in 2 patient cohorts.2Cohort A included men with high-risk, locally advanced prostate cancer, and the researchers assessed the c...
FDA不良反应(企) 药物警戒(企) 疾病分类与代码(ICD) 临床路径 临床合理用药 临床诊疗指南 兴奋剂禁用目录 辅助与重点监控用药 中国OTC目录 药物化学 原料供应 百万化合物 杂质对照品 日本MF注册 美国DMF注册 欧盟CEP认证 原料药、药用辅料和药包材登记 韩国DMF注册 结构式检索(企) ...
[18F]DCFPyL was recently approved by the FDA as a PET imaging agent for prostate cancer patients in 2021. [68Ga]Galdotadipep was used to compare the similarity in tumor targeting and in vivo biodistribution using the FDA-approved drugs, [18F]DCFPyL, and [68Ga]PSMA-11. [68Ga]Galdotadi...
TPS5101#Background:18F-DCFPyL PSMA PET imaging is now FDA approved for patients with high-risk prostate cancer and those with biochemically recurrent prostate cancer (BCR). BCR has been traditionally defined as a rising PSA after definitive surgery and/or radiation have not been curative in ...